Previous close | 2.4500 |
Open | N/A |
Bid | 1.5500 |
Ask | 3.9000 |
Strike | 5.00 |
Expiry date | 2026-01-16 |
Day's range | 2.4500 - 2.4500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Vistagen Therapeutics ( NASDAQ:VTGN ) Full Year 2024 Results Key Financial Results Net loss: US$29.4m (loss narrowed by...
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript June 11, 2024 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. […]
SOUTH SAN FRANCISCO, Calif., June 11, 2024--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update.